Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

Geoff Green Biography and Net Worth

CEO of Longeveron

Geoff Green has been with Longeveron since 2016, and is a veteran of the life sciences and drug development industry. A versatile executive with a career spanning 25 years in both public and private companies, Mr. Green has held a variety of leadership roles throughout his time in the industry. Prior to joining Longeveron, he was VP of Operations at Partikula, VP, Business Development & Clinical Affairs at Accu-Break Pharmaceuticals, President and Acting CEO of DOR BioPharma (now Soligenix (NAS: SNGX)), VP of Business Development & Operations at Heart Genomics, and Director of Clinical Affairs at Innovative Drug Delivery Systems. Early in his career he spent several years managing oncology clinical trials at Memorial Sloan-Kettering Cancer Center, and as a research associate at Paramount Capital, where he managed clinical trials for several portfolio companies. Mr. Green received a B.A. in biology from Kenyon College, and an M.B.A. from Barry University’s Andreas School of Business.

How do I contact Geoff Green?: The corporate mailing address for Mr. Green and other Longeveron executives is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. Longeveron can also be reached via phone at 305-302-7158 and via email at [email protected]. Learn More on Geoff Green's contact information.
Has Geoff Green been buying or selling shares of Longeveron?: Geoff Green has not been actively trading shares of Longeveron in the last ninety days. Most recently, on Wednesday, October 13th, Geoff Green bought 100 shares of Longeveron stock. The stock was acquired at an average cost of $38.10 per share, with a total value of $3,810.00. Learn More on Geoff Green's trading history.
Who are Longeveron's active insiders?: Longeveron's insider roster includes James Clavijo (CFO), Geoff Green (CEO), Joshua Hare (Insider), Paul Lehr (General Counsel), and Rock Soffer (Director). Learn More on Longeveron's active insiders.
Are insiders buying or selling shares of Longeveron?: During the last year, Longeveron insiders bought shares 5 times. They purchased a total of 150,436 shares worth more than $370,049.60. During the last year, insiders at the sold shares 1 times. They sold a total of 1,250 shares worth more than $2,587.50. The most recent insider tranaction occured on December, 2nd when Director Khoso Baluch sold 1,250 shares worth more than $2,587.50. Insiders at Longeveron own 19.1% of the company. Learn More about insider trades at Longeveron.
Information on this page was last updated on 12/2/2024.

Geoff Green Insider Trading History at Longeveron

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/13/2021	Buy	100	$38.10	$3,810.00

Geoff Green Buying and Selling Activity at Longeveron

Longeveron Company Overview

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Today's Range

Now: $1.76

$1.66

$1.80

50 Day Range

MA: $2.01

$1.60

$2.30

2 Week Range

Now: $1.76

$0.77

$14.80

Volume

214,958 shs

Average Volume

344,298 shs

Market Capitalization

$26.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

How Low-Cost Stocks Generate Monthly Income

From Darwin | Ad

Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!

👉 Yes, I Want the Free Report! 👈